STOCK TITAN

[6-K] IceCure Medical Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

IceCure Medical reported an executive change, delivering a notice of termination to Vice President of Operations and Services Galit Malik, with her employment ending on January 15, 2026. The company stated the termination was not related to any disagreement regarding operations, policies, or practices.

The report is furnished on Form 6-K and is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements.

IceCure Medical ha annunciato un cambiamento dirigenziale, notificando la cessazione dal ruolo di Galit Malik, Vice Presidente delle Operations and Services, con la sua idoneità terminata il 15 gennaio 2026. La società ha dichiarato che la cessazione non è legata a alcun disaccordo riguardo operazioni, politiche o pratiche.

Il rapporto è fornito su Form 6-K ed è incorporato per riferimento nelle attuali dichiarazioni di registrazione Form F-3 e Form S-8 di IceCure Medical.

IceCure Medical informó un cambio ejecutivo, notificando la terminación del cargo de Galit Malik, Vicepresidenta de Operaciones y Servicios, cuyo empleo terminará el 15 de enero de 2026. La compañía afirmó que la terminación no estuvo relacionada con ningún desacuerdo respecto a las operaciones, políticas o prácticas.

El informe se presenta en Form 6-K y se incorpora por referencia a las actuales declaraciones de registro de Form F-3 y Form S-8 de IceCure Medical.

IceCure Medical은 임원 교체를 보고했고, Galit Malik에 대한 운영 및 서비스 부사장 직무 해고 통보를 전달했으며, 그녀의 고용은 2026년 1월 15일에 종료됩니다. 회사는 해고가 운영, 정책 또는 관행에 관한 어떤 이견과도 관련이 없다고 밝혔습니다.

이 보고서는 Form 6-K에 제출되며 IceCure Medical의 기존 Form F-3Form S-8 등록 서류에 참조로 포함됩니다.

IceCure Medical a annoncé un changement dans la direction, en notifiant la résiliation du poste de Galit Malik, Vice-présidente des Opérations et des Services, dont le contrat prendra fin le 15 janvier 2026. La société a déclaré que la résiliation n'était pas liée à un quelconque désaccord concernant les opérations, les politiques ou les pratiques.

Le rapport est déposé sur le Form 6-K et est incorporé par référence dans les déclarations d'enregistrement actuelles de Form F-3 et Form S-8 d'IceCure Medical.

IceCure Medical meldete eine Führungskräfteänderung und informierte Galit Malik, die Vice President of Operations and Services, über die Kündigung, deren Anstellung am 15. Januar 2026 endet. Das Unternehmen erklärte, die Kündigung habe nichts mit einer Meinungsverschiedenheit in Bezug auf Abläufe, Richtlinien oder Praktiken zu tun.

Der Bericht wird in Form 6-K vorgelegt und ist durch Bezugnahme in den bestehenden Registrierungsunterlagen des Unternehmens Form F-3 und Form S-8 enthalten.

IceCure Medical أبلغت عن تغيير تنفيذي، مع توجيه إشعار إنهاء إلى غاليت مالك، نائبة رئيس العمليات والخدمات، حيث ينتهي توظيفها في 15 يناير 2026. ذكرت الشركة أن الإنهاء لا علاقة له بأي خلاف فيما يتعلق بالعمليات أو السياسات أو الممارسات.

يتم تقديم التقرير على Form 6-K ويتم دمجه بالإشارة في البيانات التنظيمية الحالية لـ Form F-3 و Form S-8 لدى IceCure Medical.

IceCure Medical 报告了管理层变动,向 Galit Malik、运营与服务副总裁发出解雇通知,其任职将于 2026年1月15日结束。公司表示解雇与任何关于运营、政策或做法的分歧无关。

该报告以 Form 6-K 提交,并被并入 IceCure Medical 现有的 Form F-3Form S-8 注册申报中。

Positive
  • None.
Negative
  • None.

IceCure Medical ha annunciato un cambiamento dirigenziale, notificando la cessazione dal ruolo di Galit Malik, Vice Presidente delle Operations and Services, con la sua idoneità terminata il 15 gennaio 2026. La società ha dichiarato che la cessazione non è legata a alcun disaccordo riguardo operazioni, politiche o pratiche.

Il rapporto è fornito su Form 6-K ed è incorporato per riferimento nelle attuali dichiarazioni di registrazione Form F-3 e Form S-8 di IceCure Medical.

IceCure Medical informó un cambio ejecutivo, notificando la terminación del cargo de Galit Malik, Vicepresidenta de Operaciones y Servicios, cuyo empleo terminará el 15 de enero de 2026. La compañía afirmó que la terminación no estuvo relacionada con ningún desacuerdo respecto a las operaciones, políticas o prácticas.

El informe se presenta en Form 6-K y se incorpora por referencia a las actuales declaraciones de registro de Form F-3 y Form S-8 de IceCure Medical.

IceCure Medical은 임원 교체를 보고했고, Galit Malik에 대한 운영 및 서비스 부사장 직무 해고 통보를 전달했으며, 그녀의 고용은 2026년 1월 15일에 종료됩니다. 회사는 해고가 운영, 정책 또는 관행에 관한 어떤 이견과도 관련이 없다고 밝혔습니다.

이 보고서는 Form 6-K에 제출되며 IceCure Medical의 기존 Form F-3Form S-8 등록 서류에 참조로 포함됩니다.

IceCure Medical a annoncé un changement dans la direction, en notifiant la résiliation du poste de Galit Malik, Vice-présidente des Opérations et des Services, dont le contrat prendra fin le 15 janvier 2026. La société a déclaré que la résiliation n'était pas liée à un quelconque désaccord concernant les opérations, les politiques ou les pratiques.

Le rapport est déposé sur le Form 6-K et est incorporé par référence dans les déclarations d'enregistrement actuelles de Form F-3 et Form S-8 d'IceCure Medical.

IceCure Medical meldete eine Führungskräfteänderung und informierte Galit Malik, die Vice President of Operations and Services, über die Kündigung, deren Anstellung am 15. Januar 2026 endet. Das Unternehmen erklärte, die Kündigung habe nichts mit einer Meinungsverschiedenheit in Bezug auf Abläufe, Richtlinien oder Praktiken zu tun.

Der Bericht wird in Form 6-K vorgelegt und ist durch Bezugnahme in den bestehenden Registrierungsunterlagen des Unternehmens Form F-3 und Form S-8 enthalten.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: October 2025 (Report No. 2)

 

Commission File Number: 001-40753

 

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

 

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F             ☐ Form 40-F

 

 

 

 

 

 

CONTENTS

 

On October 16, 2025, IceCure Medical Ltd. (the “Company”) delivered a notice of termination to Ms. Galit Malik, the Company’s Vice President of Operations and Services, notifying Ms. Malik that her employment contract will be terminated as of January 15, 2026. Ms. Malik’s termination was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660, 333-267272 and 333-290046) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ICECURE MEDICAL LTD.
     
Date: October 17, 2025 By: /s/ Eyal Shamir
    Name:  Eyal Shamir
    Title: Chief Executive Officer

 

 

2

 

 

FAQ

What executive change did ICCM announce?

IceCure Medical delivered a notice of termination to Vice President of Operations and Services Galit Malik.

When does Galit Malik’s termination become effective at ICCM?

Her employment contract will be terminated as of January 15, 2026.

Did the termination involve any disagreement at ICCM?

The company stated it was not related to any disagreement on operations, policies, or practices.

What filing format was used for this update by ICCM?

The update was furnished on Form 6-K.

Are any registration statements affected by this ICCM 6-K?

Yes. The 6-K is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Icecure Medical Ltd.

NASDAQ:ICCM

ICCM Rankings

ICCM Latest News

ICCM Latest SEC Filings

ICCM Stock Data

56.93M
40.78M
40.6%
0.36%
1.68%
Medical Devices
Healthcare
Link
Israel
Caesarea